Blood drive honors Romeoville boy who beat the odds—and isn't done giving back
Lewis University held a blood drive in honor of 8-year-old Caleb Koenig, who was born with TAR syndrome and once relied on monthly transfusions to survive.
Caleb's father, Chris Koenig, is head coach of the women's soccer team at Lewis University, and players—including some first-time donors—were inspired to give by Caleb's story.
Now healthy, Caleb and his family are giving back by hosting annual blood drives to support other children in need of lifesaving donations.
ROMEOVILLE, Ill. - An 8-year-old boy's battle with a rare blood disorder is inspiring the Lewis University community to roll up their sleeves and help others in need.
What we know
Members of the Lewis University women's soccer team and others donated blood in honor of Caleb Koenig, who was born with TAR syndrome — a genetic condition that severely limited his ability to produce platelets.
As a young child, Caleb required monthly blood transfusions. Thanks to the generosity of strangers, he eventually began producing platelets on his own.
Now healthy and thriving, Caleb and his family are paying it forward. This marks the third consecutive year they've hosted a blood drive in his name.
"People that we never met donated blood and because of that, he was able to get the medical treatment that he needed. So, that's why we host this and want to try to give back to the next family," said Caleb's father, Chris Koenig.
Chris Koenig is the head coach of the Lewis women's soccer team, and Caleb has become a familiar face around the program.
Goalkeeper Josie Graziosi said she overcame a fear of needles to donate blood for the first time.
"At the end of the day, when you put everything into perspective, you realize it's for a bigger cause and you can kinda push away your own worries," Josie said.
Caleb, now enjoying baseball and Taekwondo, said others who suffer from TAR syndrome will be grateful to those who donate.
His father added that seeing a face like Caleb's behind the drive makes the cause feel more personal.
What's next
For more information or to schedule a blood donation, call 1-877-258-4825.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21-07-2025
- Yahoo
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
An updated edition of the June 10, 2025, article. The global cancer treatment market is experiencing rapid growth, driven by rising cancer incidence, aging population and increasing demand for safer, more effective therapies. Per the American Cancer Society, in the United States alone, over 2 million new cancer cases and 618,000 related deaths are projected for 2025. Breakthroughs in immunotherapy, targeted treatments, and personalized cancer vaccines are reshaping the oncology landscape. These next-generation therapies offer greater precision and improved outcomes, supporting strong market expansion. Major pharma companies — including Novartis NVS, AstraZeneca AZN, Johnson & Johnson JNJ, Pfizer PFE, AbbVie ABBV, Bristol Myers Squibb and Eli Lilly LLY — are investing heavily in cutting-edge approaches like antibody-drug conjugates (ADCs) and immuno-oncology agents. Meanwhile, smaller biotechs are driving innovation, making them attractive acquisition targets for larger players seeking to enhance their oncology pipelines. As scientific progress accelerates, the oncology market is poised for robust, long-term growth — offering compelling opportunities for investors. These factors highlight the huge potential of cancer-focused companies. With our thematic screens, you can easily spot stocks tied to trends shaping the future of investing. If the cancer space appeals to you and you're looking to align your portfolio with this rising trend, now might be the time to consider stocks like J&J, Novartis and Allogene Therapeutics ALLO 3 Cancer Stocks in Focus J&J's Oncology segment comprises around 27% of its total revenues. Its oncology sales rose 22.3% on an operational basis in the second quarter of 2025 to $6.3 billion, driven by strong market growth and share gains of key products such as multiple myeloma treatment Darzalex and prostate cancer drug, Erleada. New cancer drugs, such as Carvykti, Tecvayli, Talvey and Rybrevant plus Lazcluze, contributed significantly to growth as they witnessed strong launches. On its second-quarter conference call, J&J stated that it expects its oncology sales to reach $50 billion by the end of the decade. J&J seems quite confident in the target, citing strong growth in its marketed cancer drugs and the potential of upcoming launches like TAR-200 in bladder cancer and the subcutaneous formulation of Rybrevant plus Lazcluze for advanced EGFR-mutated non-small cell lung cancer (NSCLC). TAR-200 is under priority review with the FDA for treating non-muscle invasive bladder cancer and is expected to be approved this year. The subcutaneous formulation of Rybrevant plus Lazcluze has been recommended for approval in the EU while it is under review in the United States. J&J's oncology pipeline has gained strong momentum in the last year and a half, with promising developments in colorectal and head and neck cancers. In this period, J&J had eight proof-of-concept readouts, which led the candidates to move to late-stage pivotal studies across the portfolio. J&J has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Novartis has a diverse oncology portfolio, including targeted therapies and immunotherapies. The FDA's approval of Kisqali, its CDK4/6 inhibitor for the first-line treatment of postmenopausal women with HR+/HER2 advanced or metastatic breast cancer, significantly boosted the company's oncology portfolio, with the drug now being one of the top growth drivers for the company. In particular, Kisqali has shown robust uptake in the metastatic breast cancer setting. The recent approval of a broader label for Kisqali in the United States and the EU should further fuel its sales. Kisqali recorded sales of $1.1 billion in the second quarter of 2025, up 64% year over year. Other new oncology drugs like Pluvicto (PSMA-positive metastatic castration-resistant prostate cancer) and Scemblix (chronic myeloid leukemia) also put up a stellar performance, setting the momentum for the coming years as well. Novartis' oncology sales rose 20% in constant currency terms to $4.3 billion in the second quarter of 2025. In 2024, Novartis acquired Mariana Oncology and Germany-based MorphoSys AG, which strengthened its oncology pipeline. This Zacks Rank #2 company is also investing in research to develop treatments for both common and rare cancers, focusing on precision medicine strategies. Allogene Therapeutics is focused on developing allogeneic CAR T therapies for treating cancer, especially hematologic indications with high unmet needs. This Zacks Rank #2 company has multiple pipeline candidates in the clinical stage of development, including CAR T cell product candidates — cemacabtagene ansegedleucel (cema-cel or formerly ALLO-501A) and ALLO-316 for cancer indications. Lead candidate, cema-cel, is being developed as a frontline treatment for patients with large B-cell lymphoma (LBCL). In this regard, the company has initiated the pivotal phase II ALPHA3 study to evaluate cema-cel in patients with first-line LBCL. ALLO-316, the company's first CAR T candidate for solid tumors, is being evaluated in the TRAVERSE study in adults with advanced or metastatic renal cell carcinoma. Data from the study has shown that the therapy-induced early anti-tumor activity with deepening responses over time, especially in heavily pre-treated patients with high CD70 expression. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Tom's Guide
17-07-2025
- Tom's Guide
In your 50s? Physio shares expert tips for staying fit and healthy while protecting your joints
There are some features of a healthy lifestyle that apply to people of all ages, like regular exercise, a balanced diet and getting enough sleep. As you get older, however, your approach does have to be more considered to ensure that you give the body what it needs to stay healthy without demanding too much from it. Beth Lewis is a physiotherapist at Hooke Fitness who regularly deals with clients asking about the right way to stay fit and healthy as they get older. While there is no one perfect way to train that works for everyone, there are factors that you need to consider as you get older that are similar for most people. Use this expert advice from Lewis to help you shape your training through your 50s to not only keep yourself fit and healthy in this decade, but also the decades to come. 'In your 50s, hormonal changes become more pronounced and recovery slows,' says Lewis. 'Joint degeneration risk rises, especially in the knees, hips and lower back. 'If you have been strength training through your younger years, there is no reason that that needs to change in your 50s. There are a few extra things to consider to ensure that you stay fit and healthy. As ever, a thorough warm-up and cool-down are essential when training.' Get instant access to breaking news, the hottest reviews, great deals and helpful tips. This is how Lewis suggests you should approach a week of training when you're in your 50s. This is just a suggestion — there's no one-size-fits-all approach that will work for everyone — but the following should help you plan what to do with your workouts. 'Shift to lighter weights, higher reps — 10–15 per set — and a slower tempo,' says Lewis. 'Use machines, resistance bands, or bodyweight to reduce joint loading. Incorporate Pilates for a strong core to help prevent back pain and help with a sturdy posture.' 'Incorporate daily mobility drills and balance training, for example, single-leg stance and tandem walking,' says Lewis. 'These reduce injury risk and improve posture and coordination.' 'Activities like cycling, swimming, elliptical, or hiking protect joints while keeping the heart healthy,' says Lewis. This is something you have to take care of at every age, but certainly as you get older. Along with your workouts, you have to take time to recover and be proactive about it. Lewis recommends focusing on sleep, hydration and soft tissue care through massages, foam rolling and stretching. Also, make sure you get any niggles checked out before they become full-blown injuries and have regular rest days. Certain injuries become more common as you age, so look out for tight hips and stretch your back. 'Tight hip flexors and reduced thoracic mobility are common due to desk-based work,' says Lewis. 'Daily hip openers like the couch stretch and thoracic extensions and rotations can relieve discomfort and improve overall posture." Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
Yahoo
16-07-2025
- Yahoo
Martin Lewis urges more than a million pensioners to claim benefit worth at least £3,800
Money expert Martin Lewis has issued a fresh call for eligible pensioners to check if they could get thousands of pounds a year through an 'underclaimed' government benefit. Attendance Allowance is designated for pensioners aged 66 and over who have a disability or health condition severe enough to require regular assistance. The benefit administered by the Department for Work and Pensions (DWP) offers two rates, potentially providing an extra £3,842.80 or £5,644 annually. Crucially, eligibility is not dependent on income or savings, meaning anyone who qualifies will receive the payment regardless of their financial circumstances. Writing to followers in his latest Money Saving Expert newsletter, Mr Lewis said: 'For many older people who are ill or start to face mental or physical disability, life doesn't just get tougher, it gets costlier too. 'That's why 18 months ago we launched our Attendance Allowance guide and awareness campaign, and successes have flooded in since. Yet it remains massively underclaimed.' Over one million eligible pensioners could be missing out, according to Martin Lewis (ITV) He adds that an estimated 1.1 million eligible pensioners are missing out on the benefit, according to figures from Policy in Practice, meaning that more awareness is needed. A wide range of common health conditions could qualify a person for Attendance Allowance, including arthritis, blindness, heart disease, Parkinson's, and asthma. The two payment rates depend on the level of care required. The higher rate is worth £110.40 a week, while the lower rate provides £73.90 a week. Although the DWP states the benefit is intended to help with care costs, recipients are free to spend the money as they wish. How to claim Attendance Allowance To be eligible for Attendance Allowance, applicants must have reached pension age, which is currently 66. The benefit can be claimed irrespective of state pension payments, savings, or whether the individual is still earning a regular income. The application form is lengthy, but charities such as Citizens Advice and Age UK offer support with the process and provide tips for online applications. To be eligible, an applicant must have a physical disability, mental disability, or health condition severe enough to necessitate help for their own or someone else's safety (Getty Images) To be eligible, an applicant must have a physical disability, mental disability, or health condition severe enough to necessitate help for their own or someone else's safety, and this assistance must have been required for at least the past six months. To qualify for the lower rate, frequent supervision or attention is needed during the day or night. The higher rate applies if this is required both day and night, or if the individual is nearing the end of their life. Applicants must also be in Great Britain when they claim, and have been in the country for at least two of the last three years. Agents from the DWP typically make decisions based on the information provided in the form, making it essential to include all relevant details, such as a national insurance number, NHS number, prescription and hospital records. This process means most applicants will not undergo an in-person assessment, although it is possible "if it's unclear how your disability or health condition affects you," the DWP states, in which case a medical professional will conduct an examination. It is important to note that Attendance Allowance cannot be claimed if the individual is already receiving Personal Independence Payment (PIP) or Disability Living Allowance (DLA).
